Stockscreener 앱 받기
31.63
9.48%
2.74
시간 외 거래:
31.66
0.03
+0.09%
Vera Therapeutics Inc 주식(VERA)의 최신 뉴스
VERA Stock Surges After Drug To Treat Rare Kidney Disease Gets FDA Approval – Retail Sees The Move As Catalyst For Vera Therapeutics - Stocktwits
Vera Therapeutics Stock (VERA) Opinions on Positive eGFR Data Release - Quiver Quantitative
Vera Therapeutics Shares Up 9.7% as $425,000 Drug Launch Puts Focus on Cash Reserves - TechStock²
Vera Therapeutics Climbs as Investors React to TRUTAKNA Launch Progress and Near-Term IgAN Milestones - Quiver Quantitative
Kynam Capital (VERA) now holds 4.01% beneficial stake in Vera Therapeutics - Stock Titan
Vera Therapeutics (NASDAQ:VERA) Shares Gap UpHere's Why - MarketBeat
HC Wainwright Has Positive Estimate for VERA Q3 Earnings - MarketBeat
Vera stock rises on FDA review for kidney drug (VERA:NASDAQ) - Seeking Alpha
Is Vera Therapeutics (VERA) Undervalued On FDA Approval For TRUTAKNA? - Sahm
(VERA) Volatility Zones as Tactical Triggers - Stock Traders Daily
Vera Therapeutics president and CEO Marshall Fordyce sells $701,769 in stock - Investing.com
Vera Therapeutics president and CEO Marshall Fordyce sells $1.96m in stock - Investing.com
Vera Therapeutics CEO Marshall Fordyce sells $679,747 in stock - Investing.com
Vera Therapeutics CEO Marshall Fordyce sells $679,747 in stock By Investing.com - Investing.com Nigeria
Vera Therapeutics (VERA) CEO trades 18,500 shares via 10b5-1 option exercise - Stock Titan
Vera Therapeutics (VERA) CEO option exercise and 18,500-share sale under 10b5-1 plan - Stock Titan
Goldman Sachs lowers Vera Therapeutics stock price target to $80 By Investing.com - Investing.com Nigeria
H.C. Wainwright cuts Vera Therapeutics stock price target on competition By Investing.com - Investing.com Nigeria
Vera Therapeutics (NASDAQ:VERA) Given New $90.00 Price Target at HC Wainwright - MarketBeat
H.C. Wainwright cuts Vera Therapeutics stock price target on competition - Investing.com India
E. Ohman J or Asset Management AB Acquires 42,787 Shares of Vera Therapeutics, Inc. $VERA - MarketBeat
Vera Therapeutics, Inc. Stock 12‑Month Price Target Cut to $81.21, Implies 157% Upside - TradingView
Wedbush Lowers Vera Therapeutics (NASDAQ:VERA) Price Target to $34.00 - MarketBeat
Vera Therapeutics (VERA) Stock Analysis: A Biotech With Potential 157.85% Upside - DirectorsTalk Interviews
Vera Therapeutics (VERA) Short Interest & Short Float | Updated Aug 2026 - MarketBeat
VERA SWOT Analysis: Accelerated Approval of TRUTAKNA Marks a Key Milestone - GuruFocus
Vera Therapeutics Q2 Results: Net loss widens to $109.5 million - scanx.trade
Vera Therapeutics Q2 Results: EPS beats estimates despite wider losses - scanx.trade
Vera Therapeutics Q2 loss widens less than expected - TradingView
Vera Therapeutics (NASDAQ:VERA) Announces Quarterly Earnings Results - MarketBeat
Vera Therapeutics reports Q2 net loss of $109.5M as TRUTAKNA receives FDA accelerated approval - TradingView
Vera Therapeutics (VERA) ramps spending ahead of TRUTAKNA launch and posts $230.5M loss - Stock Titan
Vera Therapeutics Provides Business Update and Reports Second Quarter 2026 Financial Results - The Manila Times
Vera's TRUTAKNA Gets FDA Accelerated Approval for IgA Nephropathy - Stock Titan
Dimensional Fund Advisors LP Decreases Stock Position in Vera Therapeutics, Inc. $VERA - MarketBeat
Vera Therapeutics (VERA) Earnings Date and Reports 2026 - MarketBeat
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
State Street Corporation (VERA) discloses 4.1M-share stake in Vera Therapeutics - Stock Titan
The Manufacturers Life Insurance Company Cuts Stock Position in Vera Therapeutics, Inc. $VERA - MarketBeat
Equity awards for Vera Therapeutics (VERA) Chief Regulatory Officer - Stock Titan
Vera Therapeutics under pressure in first earnings since approval By Investing.com - Investing.com Canada
Vera Therapeutics names Nancy Lee Boman as chief regulatory officer in initial beneficial ownership filing - Bitget
Vera Therapeutics, Inc. (VERA) Stock Analysis: A Biotech With 153% Potential Upside - DirectorsTalk Interviews
Vera Therapeutics (NASDAQ:VERA) Stock Price Down 5.8%Here's Why - MarketBeat
Price-Driven Insight from (VERA) for Rule-Based Strategy - Stock Traders Daily
BlackRock (NYSE: BLK) discloses 5.34M-share Vera Therapeutics (VERA) stake - stocktitan.net
Vera Therapeutics (VERA) Expected to Announce Earnings on Tuesday - MarketBeat
Vera Therapeutics Inc (VERA) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Vera Therapeutics Inc (VERA) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Vera Therapeutics Inc (VERA) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Vera Therapeutics Inc (VERA) Valuation: PE, PB & Fair Value Analysis - TradingKey
Vera Therapeutics Inc (VERA) Balance Sheet - TradingKey
First Light Asset Management LLC Lowers Stock Holdings in Vera Therapeutics, Inc. $VERA - MarketBeat
Vera Therapeutics, Inc. Revenue Breakdown – NASDAQ:VERA - TradingView
VERA|Vera Therapeutics Inc|Price:35.450|Chg%:-0.900 - TradingKey
Vera Therapeutics Inc (VERA) Institutional Confidence - TradingKey
Vera Therapeutics, Inc. (NASDAQ:VERA) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Fifth Third Bancorp Purchases Shares of 35,492 Vera Therapeutics, Inc. $VERA - MarketBeat
Price to book forward of Vera Therapeutics, Inc. – NASDAQ:VERA - TradingView
Vera Therapeutics (VERA) 2024 Cantor Fitzgerald Global Healthcare Conference Summary - Quartr
0.52%
0.07%
자본화:
|
볼륨(24시간):